U.K. regulators on Thursday approved a therapy that uses CRISPR gene editing technology to treat two blood disorders. U.S. federal regulators are poised to approve that same treatment in December.

The exa-cel therapy, which goes by the brand name Casgevy, is the world’s first CRISPR therapy for humans to be approved for the market.

CRISPR is a gene editing technology that acts as a pair of “genetic scissors,” allowing scientists to edit sections of DNA by “snipping” specific portions of it and replacing them with new segments. First announced in a 2012 paper, CRISPR is celebrated as a cheap and easy way to edit genes.

Posted in

Roli

Leave a Comment

You must be logged in to post a comment.